Traitements2programmes
Essais1liés
Publications2liées
SourceDBlocale

Traitements

2
MoléculeIndication / populationPhaseObjectifPaysRésultat
NaviFUS SystemParticipants with drug-resistant epilepsy (DRE) enrolled in this study will receive focused ultrasound (FUS) treatment with the NaviFUS System, guided by the neuronavigation system to evaluate the safety and efficacy of using NaviFUS System. During the treatment, the FUS will electronically scan and target to the assigned zones on one or both of the hippocampi. The study consists of a 60-day screening period for baseline observation prior to treatment, a FUS treatment period of 2 weeks for Cohort 1 or 3 weeks for Cohort 2 with 2 FUS treatments per week using the NaviFUS System, and a safety follow-up period of 81 days. Épilepsie Non applicable À vérifier Australia À vérifier
NaviFUS SystemParticipants with drug-resistant epilepsy (DRE) enrolled in this study will receive focused ultrasound (FUS) treatment with the NaviFUS System, guided by the neuronavigation system to evaluate the safety and efficacy of using NaviFUS System. During the treatment, the FUS will electronically scan and target to the assigned zones on one or both of the hippocampi. The study consists of a 60-day screening period for baseline observation prior to treatment, a FUS treatment period of 2 weeks for Cohort 1 or 3 weeks for Cohort 2 with 2 FUS treatments per week using the NaviFUS System, and a safety follow-up period of 81 days. Épilepsie Non applicable À vérifier Australia À vérifier

Essais cliniques

1
MoléculeIndication / populationPhaseNCTTitreStatut
NaviFUS System Épilepsie Non applicable NCT05947656 Evaluation of the NaviFUS System in Drug Resistant Epilepsy RECRUITING

Publications

2
MoléculeIndication / populationTitreJournalDate
NaviFUS System A randomized feasibility pilot trial of a remotely delivered physical activity intervention for adults with epilepsy. Epilepsy & behavior : E&B
NaviFUS System Focused ultrasound-induced blood-brain barrier modulation for drug delivery in recurrent glioblastoma: A systematic review. The Indian journal of medical research